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ABSTRACT 
Rationale:  Nucleus accumbens dopamine (DA) participates in the modulation of instrumental behavior, 
including aspects of behavioral activation and effort-related choice behavior. Rats with impaired 
accumbens DA transmission reallocate their behavior away from food-reinforced activities that have high 
response requirements, and instead select less-effortful types of food-seeking behavior. Although 
accumbens DA is considered a critical component of the brain circuitry regulating effort-related 
processes, emerging evidence also implicates adenosine A2A receptors. Objective: The present work was 
undertaken to test the hypothesis that accumbens A2A receptor stimulation would produce effects similar 
to those produced by DA depletion or antagonism. Methods: Three experiments assessed the effects of the 
adenosine A2A agonist CGS 21680 on performance of a concurrent choice task (lever pressing for 
preferred food vs. intake of less preferred chow) that is known to be sensitive to DA antagonists and 
accumbens DA depletions. Results: Systemic injections of CGS 21680 reduced lever pressing but did not 
increase feeding. In contrast, bilateral infusions of the adenosine A2A receptor agonist CGS 21680 (6.0-
24.0 ng) into the nucleus accumbens decreased lever pressing for the preferred food, but substantially 
increased consumption of the less preferred chow. Injections of CGS 21680 into a control site dorsal to 
the accumbens were ineffective. Conclusions: Taken together, these results are consistent with the 
hypothesis that local stimulation of adenosine A2A receptors in nucleus accumbens produces behavioral 
effects similar to those induced by accumbens DA depletions. Accumbens adenosine A2A receptors appear 
to be a component of the brain circuitry regulating effort-related choice behavior.  
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Introduction 
Motivated behavior can be characterized by vigor, persistence, and high levels of work output.  
These activational aspects of motivated behavior have enormous adaptive significance because they 
enable organisms to overcome obstacles or work-related response costs that separate them from 
significant stimuli (Salamone 1991, 1992; Salamone et al. 1997, 2003, 2007; Salamone and Correa 2002; 
Van den Bos et al. 2006; Walton et al. 2006). Moreover, pathologies related to behavioral activation, such 
as psychomotor slowing, anergia, and fatigue, are recognized as critical aspects of depression and other 
psychiatric disorders (Tylee et al. 1999; Stahl 2002; Salamone et al. 2006, 2007).  Over the past two 
decades, considerable research has demonstrated that nucleus accumbens DA is a critical component of 
the brain circuitry controlling effort-related behavioral processes (Salamone et al. 1991, 1994, 1997, 
2002, 2007; Phillips et al. 2007; Niv et al. 2007).  Depletions of DA in nucleus accumbens make animals 
highly sensitive to ratio requirements in operant schedules (Sokolowski and Salamone 1998; Aberman 
and Salamone 1999; Correa et al. 2002; Mingote et al. 2005).  Furthermore, studies involving choice 
behavior have shown that rats administered DA receptor antagonists or rats with accumbens DA 
depletions reallocate their behavior away from food-reinforced tasks that have high response 
requirements, and instead select less-effortful types of food-seeking behavior (Salamone et al. 1991, 
1997, 2003, 2005, 2006, 2007). Some of these studies utilized maze tasks to assess effort-related choice 
(Salamone et al. 1994; Cousins et al. 1996; Denk et al. 2005; Floresco et al. 2007).  In addition, several 
studies have employed a concurrent fixed Ratio 5 (FR5)/chow feeding procedure (Salamone et al. 1991). 
With this procedure, rats are allowed to choose between completing a FR5 lever-pressing requirement for 
a highly palatable food (i.e., high carbohydrate operant pellets) or to approach and consume freely 
available food (i.e., less palatable standard rodent chow). Rats trained using this procedure spend most of 
their time pressing the lever for the preferred food, and eat very little of the concurrently available chow. 
Low-to-moderate doses of DA antagonists with different selectivity profiles, including haloperidol, cis-
flupenthixol, SCH 23390, SCH 39166, raclopride and eticlopride, all suppress lever pressing for food, but 
actually increase chow intake (Salamone et al. 1991; Cousins et al. 1994; Koch et al. 2000; Salamone et 
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al. 2002; Sink et al. in press). In addition, rats with accumbens DA depletions or those treated with local 
intra-accumbens injections of DA antagonists also reallocate their responses in this task, showing 
decreases in lever pressing and increases in chow intake as a result of local interference with DA 
transmission (Salamone et al. 1991; Cousins et al. 1993; Sokolowski and Salamone, 1998; Koch et al. 
2000; Nowend et al. 2001).  These effects of interference with DA transmission differ substantially from 
the effects produced by pre-feeding to reduce food motivation (Salamone et al. 1991), as well as appetite 
suppressants such as amphetamine (Cousins et al. 1994), fenfluramine (Salamone et al. 2002) and 
cannabinoid CB1 antagonists and inverse agonists (Sink et al., in press), all of which fail to shift behavior 
from lever pressing to chow intake.  
Several lines of evidence indicate that, in addition to nucleus accumbens DA, other brain areas 
and transmitters are involved in effort-related processes, including prefrontal cortex, amygdala, and 
ventral pallidum (Walton et al. 2002, 2003; Schweimer et al. 2005; Schweimer and Hauber 2006; 
Floresco and Ghods-Sharifi 2007; Farrar et al. submitted). Recent studies also have highlighted the 
involvement of the purine nucleoside adenosine in this type of function (Farrar et al. 2007).  Although 
there are at least four types of adenosine receptors, adenosine A2A receptors are primarily localized in 
striatal areas, including both neostriatum and nucleus accumbens (Jarvis and Williams 1989; Schiffmann 
et al. 1991; DeMet and Chicz-DeMet, 2002; Ferré et al. 2004).  In these striatal areas there is considerable 
evidence of a functional interaction between dopamine D2 and adenosine A2A receptors (Fink et al. 1992; 
Ferré 1997; Hillion et al. 2002; Fuxe et al. 2003).  This interaction has typically been investigated in 
connection with neostriatal motor functions that are potentially related to parkinsonism (Ferré et al. 1997; 
Svenningsson 1999; Ferré et al. 2001; Hauber et al. 2001; Morelli and Pinna 2001; Jenner 2003, 2005; 
Pinna et al. 2005).  In these studies, adenosine A2A receptor antagonists have been shown to exert effects 
consistent with antiparkinsonian actions in animal models (Ferré et al. 1997, 2001; Hauber et al. 2001; 
Wardas et al. 2001; Jenner 2003; Correa et al. 2004; Pinna et al. 2005; Ishiwari et al. 2007), and 
adenosine A2A receptor antagonists are being evaluated as antiparkinsonian agents in human clinical trials 
(Jenner 2005). More recently, researchers have begun to identify potential motivational functions of 
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adenosine A2A receptors (O’Neill and Brown 2006; Cabeza de Vaca et al. 2007; Farrar et al. 2007).  
Farrar et al. (2007) described the involvement of adenosine A2A receptors in modulating the effects of DA 
blockade on behavioral performance using the concurrent FR5/feeding procedure. In this experiment, a 
low systemic dose of the DA antagonist haloperidol induced the typical shift from lever pressing to 
approaching and feeding upon the freely available rodent chow. Injections of the adenosine A2A 
antagonist MSX-3 increased lever pressing and decreased chow intake in haloperidol-treated rats, 
reversing the haloperidol-induced shift in behavior.  
Consistent with these previous findings of an interaction between DA and adenosine receptors, 
adenosine A2A agonists have been shown to induce effects that resemble those produced by DA 
antagonists or DA depletions (Heffner et al. 1989; Barraco et al. 1993; Ferré 1997; Rimondini et al. 
1997).  Administration of the adenosine A2A receptor agonist CGS 21680 into the ventricles inhibited 
acquisition and expression of wheel running behavior (Cabeza de Vaca et al. 2007).  High systemic doses 
of CGS 21680 have been shown to induce catalepsy (Wardas et al., 2003).  In addition, CGS 21680 
depressed locomotor activity when infused directly into the nucleus accumbens (Barraco et al. 1993; 
Hauber and Munkle, 1997). Although it seems clear that stimulation of adenosine A2A receptors in 
nucleus accumbens can suppress locomotor activity, relatively little is known about the role of these 
receptors in the regulation of effort-related processes.  The present studies were undertaken to determine 
if stimulation of adenosine A2A receptors in nucleus accumbens would produce behavioral effects similar 
to those produced by DA antagonism and accumbens DA depletions; these experiments all employed the 
concurrent FR5/chow feeding choice task described above. The first experiment examined the effects of 
systemic injections of the adenosine A2A agonist CGS 21680 on the concurrent FR5/chow feeding task. 
The second experiment evaluated the effects of intra-accumbens injections of CGS 21680 using the same 
procedure.  It was hypothesized that intra-accumbens injections of GGS 21680 would shift choice 
behavior from lever pressing to chow intake in a manner similar to that previously shown for 
dopaminergic manipulations. Finally, in order to demonstrate the anatomic specificity of these effects, the 
highest dose of CGS 21680 was bilaterally injected into a control site dorsal to the nucleus accumbens.  
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Materials and Methods 
Subjects 
Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) weighing between 300-
360 g at the beginning of the study (total n=49) were housed in a colony maintained at 23ºC with a 12h 
light/dark cycle (lights on at 08:00h). Rats were food restricted to 90% body weight prior to training, and 
after initial training they were allowed modest growth (e.g. up to 95% of original weight). Water was 
available ad libitum in the home cages at all times. In experiments 2 and 3 animals were housed in pairs 
before surgery and in single cages afterwards. All animal protocols were approved by the Institutional 
Animal Care and Use Committee and the methods were in accordance with the Guide for the Care and 
Use of Laboratory Animals (Institute of Laboratory Animals Resources, 1996). 
 
Drugs 
The selective adenosine A2A agonist CGS 21680 4-[2-[[6-Amino-9-(N-ethyl-β-D-
ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid hydrochloride] was purchased 
from Tocris (Ellisville, Missouri). For the systemic injections (experiment 1), CGS 21680 was dissolved 
in 2% dimethyl sulfoxide solution (DMSO, Fisher Scientific, Hampton, New Hampshire, USA). This 
solution also served as the vehicle control. For the intracranial injections (experiments 2 and 3), CGS 
21680 was dissolved in a saline solution (0.9%) at room temperature and, afterwards was sonicated for 8-
10 min. For these experiments, saline was also used as the vehicle control solution. 
 
Behavioral procedure – acquisition phase 
All the experiments were conducted in operant chambers (28x23x23 cm; Med Associates). After 
magazine training, all rats were trained for 4 days to lever press (30 min sessions; 45 mg pellets, Bioserve 
Inc., Frenchtown, NJ) on a fixed ratio (FR) 1 schedule of reinforcement. In this schedule for each lever 
press the animals receive one operant pellet (45 mg pellets, Bioserve Inc., Frenchtown, NJ). After this 
initial training, the animals were trained on a FR5 schedule (30 min sessions, 5 days/week) for 4 
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additional weeks. Rats were then trained on the concurrent FR 5/chow feeding procedure for at least 1 
week before surgery. For this procedure, weighed amounts of lab chow (typically 15-20 g, 3 large pieces) 
were concurrently available on the floor of the chamber during the FR 5 sessions. At the end of the 
session, rats were immediately removed from the chamber. Food intake was determined by calculating the 
difference between pre- and post-session food weight, including spillage, which was collected on paper 
sheets below the floor of the operant chambers.  
 
Surgery 
For guide cannulae implantations in the intracranial injection experiments, animals were 
anesthetized with a solution (1.0 ml/kg, IP) that was prepared by mixing 10 ml of 100 mg/ml ketamine 
and 0.75 ml of 20 mg/ml xylazine and placed in a stereotaxic device (David Kopf Instruments, Tujunga, 
CA). For experiment 1, animals received bilateral implantation of stainless steel guide cannulae (25 
gauge; Small Parts, Inc., Miami Lakes, FL) 1.0 mm above the nucleus accumbens (flat skull; AP +1.6 mm 
from the bregma and ±1.4 mm lateral to bregma, and –6.8 mm ventral to skull surface). Coordinates for 
placements into dorsal control site were AP + 1.6 mm from bregma, ML ±1.4 mm lateral from midline, 
and DV – 4.8 mm ventral from the surface of the skull. These coordinates were obtained from the Paxinos 
and Watson (1998) stereotaxic atlas. All guide cannulae were secured to the skull by stainless steel screws 
and by Durelon carboxylate cement (3M ESPE Dental products, St. Paul, MN, USA). A stainless steel 
stylet was inserted through each guide cannula to insure its integrity. Following surgery, animals were 
allowed to recover for a minimum of 7 days before testing.  
 
Experimental procedures 
Experiment 1: effects of systemic administration of the selective adenosine A2A agonist CGS 
21680 on the concurrent FR5/chow feeding procedure  
After the initial training with the concurrent FR5/chow feeding procedure described above, all 
animals (n=8) received IP injections of the following doses of CGS 21680: vehicle, 0.0125, 0.025, 0.05, 
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0.1, 0.2 mg/kg. This experiment used a within-groups design, with all rats receiving all drug treatments in 
a randomly varied order (one treatment per week). Baseline training (i.e., non-drug) sessions were 
conducted 4 additional days per week. All injections were given 15 minutes before the animals were put 
in the operant chambers for a 30 min session. Behavioral measures for the concurrent FR5/chow feeding 
procedure included number of food pellets obtained, number of lever presses, and grams of lab chow 
intake as described above. 
Experiment 2: effects of intracranial injections of CGS 21680 into the nucleus accumbens on the 
concurrent FR5/chow feeding procedure  
After recovering from cannulae implantation surgery, rats resumed training on the concurrent 
FR5/chow feeding procedure for 2 additional weeks. Rats were then randomly assigned to one of the 
following drug treatment groups: vehicle (n=7), 6.0 (n=7), 12.0 (n=7) and 24.0 ng/0.5 µl per side (n=7). 
On the test day, bilateral injections of vehicle or CGS 21680 into the nucleus accumbens were made 
through a guide cannula using 30-gauge injectors set to extend 1.0 mm beyond the tips of the cannulae. 
Each injector was attached via PE10 tubing to a 10.0 µl syringe driven by Harvard syringe pump. All 
injections were at a flow rate of 0.125 µl/min and the total volume injected was 0.5 µl per side. After 
injection the injector was left in place for 1 more min to allow for diffusion from the injection site. 
Directly following the injection procedure, the animals were placed in the operant boxers for a 30 min 
session on the concurrent FR5/chow feeding procedure. At the end of the session, rats were immediately 
removed from the chamber. Food intake was determined by calculating the difference between pre- and 
post-session food weight, including spillage, which was collected on paper sheets below the floor of the 
operant chambers. Other behavioral measures included number of food pellets obtained and number of 
lever presses. 
Experiment 3: effects of intracranial injections of CGS 21680 into the dorsal control sites on the 
concurrent FR5/chow feeding procedure  
The procedures followed in this experiment were the same as those in experiment 2, except that a 
different injection site was used. Once animals were recovered from surgery and presented a stable baseline 
 9 
of concurrent FR5/chow feeding, bilateral injections of either saline vehicle (n = 7) or 24.0 ng of CGS 21680 
(n = 6) were given into the control site 2 mm dorsal to the nucleus accumbens, as described above.     
 
Histology 
At the completion of behavioral testing in the intracranial injection experiments each animal was 
anesthetized with CO2.  In experiments 2 and 3, rats were perfused intracardially with physiological saline 
followed by a 3.7 % formaldehyde solution. The brains were removed and stored in formaldehyde, and 
then were sliced with a cryostat in 50-µm sections, which were mounted on glass microscope slides. 
Following mounting, slides were stained with Cresyl Violet for microscopic observation by an observer 
who was unaware of the experimental treatment. Any animal with improper cannulae placement or 
significant damage around the injection site was excluded from the statistical analyses of behavioral data 
(27% of all implantations were rejected). Final numbers of animals included in the statistical data 
analyses for each experiment are as follows: experiment 1 (n=8), experiment 2 (n = 28) and experiment 3 
(n=13).  
 
Data analysis 
For the within-subjects study (experiment 1), the total number of lever presses and the quantity of 
chow intake were analyzed with repeated measures analysis of variance (ANOVA). Non-orthogonal 
planned comparisons using the overall error term were used, with the number of comparisons being 
restricted to the number of treatments minus one (Keppel, 1991). The behavioral data for experiments 2 
and 3 that included number of lever presses and chow consumption quantities were both analyzed using 
between-subjects analyses. For each measure analyzed in these experiments, a one-way ANOVAs (CGS 
21680 doses) was conducted. Non-orthogonal planned comparisons using the overall error term were 
used, with the number of comparisons being restricted to the number of treatments minus one (Keppel 
1991). Finally, correlational analyses were used to measure the relation between lever pressing and chow 
consumption in rats treated with intra-accumbens CGS 21680.  This correlational analysis has been 
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conducted previously to provide an additional statistical marker of the shift from lever pressing to chow 
intake that was produced by interference with DA transmission (Cousins et al. 1993; Sokolowski and 
Salamone 1998; Salamone et al. 2002).  
 
Results 
Experiment 1: Effects of systemic administration of the selective adenosine A2A agonist CGS 
21680 on the concurrent FR5/chow feeding procedure  
On a concurrent FR5/chow feeding procedure, in which rats can choose between pressing the 
lever for preferred food and consuming readily available lab chow, systemic injections of CGS 21680 
produced a reduction in the number of lever presses [F(4, 28) = 46.92, p < 0.001) and no statistical 
change in the amount of chow intake [F(4, 28) = 0.640, p = 0.633]. Figures 1A and 1B show the effects 
of CGS 21680 on lever presses and chow intake, respectively. Planned comparisons revealed that 0.05, 
0.1 and 0.2 mg/kg doses of CGS 21 680 significantly reduced the number of lever presses relative to 
vehicle control (p < 0.05). 
Experiment 2: Effects of intracranial injections of CGS 21680 into the nucleus accumbens on the 
concurrent FR5/chow feeding procedure  
The results of experiment 2, in which rats received injections of CGS 21680 into the nucleus 
accumbens, are presented in Figures 2A and 2B. In this experiment, CGS 21680 dose dependently 
decreased lever pressing [F(3, 24) = 8.218, p = 0.001] and also increased chow consumption [F(3, 24) = 
7.09, p < 0.05]. Planned comparisons revealed that 6.0, 12.0 and 24.0 ng/0.5 µl per side doses of CGS 
21680 significantly reduced the number of lever presses relative to vehicle control (p < 0.05). In addition, 
planned comparisons on the chow consumption data showed that the highest dose (24.0 ng CGS 21680) 
increased chow consumption to quantities that were statistical different from vehicle (p < 0.05). 
Correlational analysis revealed that there was a significant inverse correlation between lever pressing and 
chow consumption in rats treated with CGS 21680 (Pearson correlation = -0.757, df= 19, p < 0.001).   
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Experiment 3: Effects of intracranial injections of CGS 21680 into the dorsal control site on the 
concurrent FR5/chow feeding procedure  
The results of experiment 3, in which rats received injections of CGS 21680 into a control site 
dorsal to the nucleus accumbens, are depicted in Figures 3A and 3B. Data analyses demonstrated that 
CGS 2168 (24.0 ng/0.5 µl per side) microinjected into the dorsal control area had no significant effect on 
the concurrent lever pressing/chow feeding choice task (lever pressing: t=1.07, df = 11, n.s.; chow intake: 
t = -1.1, df = 11, n.s.).  
Analysis of Histology and General Observations of Behavior 
Figure 4 shows the cannula placements for rats that received injection of CGS 21680 into the 
nucleus accumbens (experiment 2) and the control site dorsal to the accumbens (experiment 3).  Only rats 
that received 24 ng CGS 21680 are shown.  Placements in the accumbens were generally in core, or 
adjacent areas of dorsomedial shell.  Among animals in the dorsal control experiment, cannula placements 
were generally in the anterior/medial part of the neostriatum dorsal to nucleus accumbens.  
Overt signs of sedation were noted by experimenters as they placed animals in and out of the test 
chambers.  In experiment 1, some of the rats that received 0.05 mg/kg CGS 21680 and all the animals that 
received 0.1 and 0.2 mg/kg CGS 21680 showed overt signs of sedation (e.g. eyes partially closed, head 
lowered).  None of the animals in the intracranial experiments (i.e., experiments 2 or 3) showed overt 
signs of sedation after injections of CGS 21680. 
 
Discussion 
The present studies demonstrated that systemic injections of CGS 21680 produced a dose-related 
suppression of FR5 lever pressing, but that drug-treated rats with reduced levels of responding failed to 
show corresponding increases in chow intake. Thus, the effects of systemic administration of an 
adenosine A2A agonist did not produce effects that closely mimic the actions of low doses of DA 
antagonists, or accumbens DA depletions. Nevertheless, local injections of CGS 21680 into the nucleus 
accumbens did induce a shift from lever pressing to chow intake. These studies support the hypothesis 
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that stimulation of  adenosine A2A receptors in nucleus accumbens can produce effects that resemble those 
resulting from accumbens DA depletions or DA receptor antagonism, and also highlight differences 
between the effects of systemic and intra-accumbens injections of CGS 21680. 
The behavioral procedure used in the present studies provides information about the allocation of 
behavior in the context of an operant conditioning environment that allows for choices between 
alternative paths that lead to food. Rats can choose between lever pressing on a FR5 schedule to obtain a 
preferred food, or approaching and feeding upon a less preferred lab chow that is concurrently available. 
Intact animals trained on this procedure generally receive most of their food by pressing the lever for food 
pellets, and tend to eat little of the concurrently available but less preferred chow (Salamone et al. 1991; 
Cousins et al. 1993; Cousins and Salamone 1994; Salamone et al. 1995; Cousins et al. 1996; Nowend et 
al. 2001; Salamone et al. 2002; Farrar et al. 2007). However, rats injected with low doses of DA 
antagonists, or rats with accumbens DA depletions, reallocate their behavior towards the less effortful 
food-seeking behavior, i.e., animals with decreased lever pressing show a substantial increase in feeding 
upon the rodent chow (Salamone et al. 1991; Cousins et al. 1993, 1994; Cousins and Salamone 1994; 
Sokolowski and Salamone 1998; Koch et al. 2000; Nowend et al. 2001; Salamone et al. 2002).  The 
results of these studies have been interpreted to mean that interference with nucleus accumbens DA 
transmission changes the pattern of choice behavior, altering the relative allocation of food-related 
responses away from lever pressing and towards approach and consumption of chow (Salamone et al. 
1997; 2003; 2007).  Farrar et al. (2007) recently showed that systemic administration of the adenosine 
A2A antagonist MSX-3 could attenuate the effects of the DA antagonist haloperidol in rats performing on 
the concurrent FR5/chow intake procedure. This finding suggests that adenosine A2A receptors participate 
in the effort-related functions of nucleus accumbens, and the present studies were undertaken to 
determine if stimulation of adenosine A2A receptors in nucleus accumbens could produce effects that 
resemble those produced by accumbens DA depletions or DA receptor antagonism.  
Experiments 1 and 2 examined the effects of systemic and intra-accumbens injections of the 
adenosine A2A agonist CGS 21680 using the concurrent lever pressing/chow intake procedure. The results 
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of the systemic administration study (experiment 1) showed the predicted dose-related suppression of 
FR5 lever pressing, which is consistent with a previous paper demonstrating that CGS 21680 could 
reduce lever pressing rates in rats responding on cocaine and methamphetamine drug discrimination tasks 
(Justinova et al., 2003). However, in experiment 1 there were no corresponding increases in chow intake 
in drug-treated rats. Thus, systemic administration of an adenosine A2A agonist did not produce effects 
that closely mimic the effects of low doses of a DA antagonist, or accumbens DA depletions. 
Nevertheless, as hypothesized, local injections of CGS 21680 into the nucleus accumbens decreased lever 
pressing and increased chow intake. Thus, although lever pressing was decreased by intra-accumbens 
CGS 21680, animals showed a compensatory reallocation of their behavior to the alternative choice (i.e. 
approaching and eating the freely available chow). In agreement with these observations, correlational 
analyses revealed a strong inverse relation between lever pressing and chow intake across drug 
treatments. This robust inverse correlation between lever pressing and chow intake in drug-treated 
animals has been a reliable statistical marker of the shift from lever pressing to chow intake that is 
induced by dopaminergic manipulations (Cousins et al. 1993; Nowend et al. 2001; Salamone et al. 2002; 
Sink et al. in press).  In view of these results, it appears as though the hypothesis that local stimulation of 
adenosine A2A receptors could produce effects similar to interference with DA transmission was 
confirmed. Furthermore, in the present study, local infusion of CGS 21680 into a site 1 mm above the 
nucleus accumbens into anterior/medial dorsal striatum failed to produce any significant effect on lever 
pressing or chow consumption. For these reasons, it is unlikely that diffusion to other brain areas accounts 
for the effects observed after intra-accumbens injections. The present studies used a nucleus accumbens 
placement that was more or less intermediate between core and shell subregions of the accumbens (see 
figure 4), and future studies should specifically investigate placements into core and shell areas (e.g., 
Nowend et al. 2001).  
As described above, systemic injections of CGS 21680 had a large suppressive effect on operant 
responding that was not accompanied by an increase in chow consumption, which was quite distinct from 
the effects produced by intra-accumbens injections of CGS 21680. There could be several reasons why IP 
 14 
administration of CGS 21680 produced different effects than intra-accumbens injections. One of the 
likely explanations is that systemic administration of an adenosine A2A agonist such as CGS 21680 
produces sedation (i.e., drowsiness). The sedative effects of adenosine have been well characterized 
(Satoh et al. 1998; Porkka-Heiskanen et al. 2000; Scammell et al. 2001; Hong et al. 2005; Stenberg 2007). 
Systemic or intraventricular injections of adenosine, as well as local infusions into the basal forebrain, 
have been shown to induce sleep (Stenberg 2007). Sleep deprivation is associated with increases in the 
extracellular levels of adenosine, and non-selective adenosine antagonists such as caffeine are used to 
enhance wakefulness (Stenberg 2007). Evidence indicates that both adenosine A1 and A2A receptors are 
involved in the regulation of sleep, though probably through different mechanisms and distinct brain areas 
(Stenberg 2007). Several studies have reported that systemic administration of CGS 21680, or local 
injections into the basal forebrain, induce sleep (Satoh et al. 1998; Porkka-Heiskanen et al. 2000; 
Scammell et al. 2001; Hong et al. 2005; Stenberg 2007). Knockout of adenosine A2A receptors in mice 
results in a loss of sensitivity to the sedative effects of adenosine A2A agonists, and in these studies it was 
shown that an adenosine A2A agonist could induce sleep in wild type mice (Satoh et al. 1998). Thus, it is 
possible that systemic administration of CGS 21680 decreased lever pressing but failed to increase 
feeding because of a drug-induced sedation effect (i.e., induction of drowsiness, which produced a non-
selective suppression of several behaviors), which is consistent with the behavioral observations of rats 
treated with systemic CGS 21680 (see above). Interestingly, the atypical antipsychotic clozapine, which is 
known to produce sedation, decreased the number of lever presses and, like CGS 21680, failed to increase 
chow consumption in the FR5/chow feeding procedure at doses that also produced observable sedative 
effects (Salamone et al. 1996). 
Consistent with these observations, recent studies from our laboratory indicate that systemic 
administration of CGS 21680 produced a broad of suppression of behavior that was accompanied by 
marked sedation and drowsiness (Mingote et al. submitted). This study employed a sedation rating scale 
adapted from Salamone et al. (1996) and Chuck et al. (2006), and showed that, in the same systemic dose 
range that also suppressed FR5 lever pressing and feeding, CGS 21680 (0.05 and 0.1 mg/kg IP) 
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significantly induced overt signs of sedation/drowsiness that included foot dragging, stumbling, ataxia, 
flattened posture, lowered head, and partially closed eyes. In the Mingote et al. (submitted) study, 0.1 
mg/kg CGS 21680 produced a level of sedation that was comparable to that induced by 2.0 g/kg ethanol 
(Chuck et al. 2006), which is a dose of ethanol that also suppressed lever pressing. Thus, the absence of a 
shift from lever pressing to chow intake following systemic administration of CGS 21680 may be due to a 
sedation/drowsiness effect. It is possible that intra-accumbens injections of CGS 21680 bypassed these 
sedative effects, and in fact the experimenters did not note any overt signs of sedation in rats that received 
intra-accumbens injections of CGS 21680; this lack of sedation could have allowed the predicted shift in 
behavior from lever pressing to chow intake to occur.  
In addition to sedation, there are other possible mechanisms through which systemic injections of 
CGS 21680 could be acting to keep levels of feeding low in animals with suppressed operant responding. 
For example, IP administration of CGS 21680 is likely to be stimulating neostriatal adenosine A2A 
receptors, as well as those in nucleus accumbens. Several lines of evidence indicate that ventrolateral 
neostriatum (VLS) is a critical area in regulating orofacial and forepaw motor control (Heimer et al. 1985; 
McGeorge et al. 1989; Cousins et al. 1996; 1999). Previous work has demonstrated that DA depletions in 
the VLS reduce both lever presses and chow consumption in rats responding on the concurrent FR5/chow 
intake task (Cousins et al. 1993). Depletions of DA in the VLS induced profound deficits in feeding that 
are related to impairments in feeding rate and a loss of the ability to handle the food (Cousins et al. 1993; 
Salamone et al. 1993). Consistent with this idea, recent studies have demonstrated that systemic 
administration of CGS 21680 in doses of 0.05 mg/kg or higher can induce feeding impairments, which 
are marked by a significant reduction in the rate of feeding (Mingote et al. submitted).  Thus, it is possible 
that motor impairments related to neostriatal functions also contributed to the generally low levels of both 
lever pressing and feeding after IP injections of CGS 21680. Finally, it is possible that systemic CGS 
21680 acted to suppress appetite or produce food aversions. Previous work showed that appetite 
suppressants such as amphetamine and fenfluramine decreased lever pressing but failed to increase chow 
intake in animals responding on the choice procedure (Cousins et al. 1994; Salamone et al. 2002). More 
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recent data indicate that CB1 antagonists and inverse agonists, which act either to suppress appetite or 
induce food aversions, also decrease lever pressing but fail to increase chow intake in rats tested on the 
concurrent choice procedure (Sink et al. in press). Any one of these actions (sedation, motor impairment, 
appetite suppression or food aversion) could have contributed to the effects of systemic CGS 21680, and 
it is possible that some combination of these actions led to the results of experiment 1. 
The present experiments demonstrated clearly that adenosine transmission can regulate operant 
responding. Yet, they also illustrated that systemic injections of an adenosine A2A receptor agonist can 
have different behavioral effects than those produced by injections into the nucleus accumbens. Systemic 
administration of CGS 21680 produced effects that were quite broad, probably resulting from stimulation 
of A2A receptors in several distinct brain regions that regulate a variety of different functions. In contrast, 
the behavioral effects of stimulation of adenosine A2A receptors in the nucleus accumbens tended to be 
more selective, and they more closely resembled those effects produced by accumbens DA depletions or 
local DA antagonism. Thus, our data establish a parallel between the behavioral consequences of 
stimulating adenosine A2A receptors in the nucleus accumbens and earlier findings in which accumbens 
DA depletions or local DA antagonism altered the relative allocation of food-related responses away from 
lever pressing and towards approach and consumption of chow. Both dopaminergic and adenosinergic 
manipulations appear to make animals more sensitive to the work requirements of a task. These findings 
suggest a possible functional interaction between DA and adenosine in the nucleus accumbens that 
modulates effort output in motivated behavior. In addition to being involved in the regulation of normal 
motivated behavior, it also is possible that adenosine transmission in the nucleus accumbens is involved 
in pathological aspects of behavioral activation, such as anergia or psychomotor slowing in depression 
(Salamone et al. 2006, 2007). Additional research into the function of adenosine A2A receptors, as well as 
associated forebrain systems, may lead to a greater understanding of both normal and pathological 
features of motivation, and may also promote the development of novel treatments for effort-related 
disorders in humans. 
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Figure Captions. 
 
Figure 1. Systemic injections of CGS 21680. A. Effects of systemic injections of CGS 21680 on the lever 
pressing on the FR 5/chow feeding procedure. Mean (± S.E.M.) number of lever presses after injections 
of vehicle and different doses of CGS 21680. B. Effects of systemic injections of CGS 21680 on chow 
consumption on the FR 5/chow feeding procedure. Mean (± S.E.M.) weight of chow intake in grams after 
injections of vehicle and different doses of CGS 21680. (* different from vehicle, p < 0.05) 
 
Figure 2. Intra-accumbens injections of CGS 21680 A. Effects of intracranial injections of CGS 21680 
into the nucleus accumbens on lever pressing on the FR 5/chow feeding procedure. Mean (± S.E.M.) 
number of lever presses for rats that received injections of vehicle or different doses of CGS 21680. B. 
Effects of intra-accumbens injections of CGS 21680 on chow consumption on the FR 5/chow feeding 
procedure. Mean (± S.E.M.) weight of chow intake in grams after injections of vehicle or different doses 
of CGS 21680. (* different from vehicle, p < 0.05). 
 
Figure 3. Dorsal control injections of CGS 21680. A. Effects of intracranial injections of CGS 21680 into 
a control site dorsal to the accumbens on lever pressing on the FR5/chow feeding procedure. Mean (± 
S.E.M.) number of lever presses during 30 min session in rats treated with vehicle or CGS 21680. B. 
Effects of intracranial injections of CGS 21680 into the dorsal control site on the chow consumption. 
Mean (± S.E.M.) weight of chow intake in grams during 30 min session after injections of vehicle or CGS 
21680.  
 
Figure 4. This figure, which was adapted from Paxinos and Watson (1996), shows the cannulae 
placements for rats that received bilateral injections of the highest dose of CGS 21680 (24.0 ng) in the 
nucleus accumbens in experiment 2 (open circles) and the dorsal control site in experiment 3 (gray 
triangles). cpu= caudate/putamen; acc = nucleus accumbens 
